DUBLIN--(BUSINESS WIRE)--The "2018 Dyspepsia Drug Development- Pipeline Analysis Report" report has been added to ResearchAndMarkets.com's offering.
To assist investigators and funding and regulatory organizations, the publisher has come up with a comprehensive report on Dyspepsia pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.
Current status, developmental phase, participating companies and entities, recent developments, orphan drug/ fast track/ other designations, drug class are provided for each Dyspepsia pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.
In addition to complete details of each product, the report provides key trends in Dyspepsia pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
Key Topics Covered:
1 Dyspepsia Pipeline Analysis
2 Dyspepsia - Company Wise Pipeline Analysis
3 Dyspepsia R&D Pipeline Snapshots
4 Recent Developments in Dyspepsia Pipeline
5 Appendix
Companies Featured
- Abide Therapeutics
- Daewoong Pharmaceutical Co Ltd
- Dong-A ST Co., Ltd.
- IlDong Pharmaceutical Co Ltd
- LTT Bio-Pharma Co Ltd
- RaQualia Pharma Inc
- Renexxion LLC
- Rottapharm
- Zensun (Shanghai) Sci & Tech
- Zeria Pharmaceutical Co Ltd
For more information about this report visit https://www.researchandmarkets.com/research/nvxff9/dyspepsia_drug?w=4
